What is Orbem?
Orbem operates at the intersection of deep-tech and industrial efficiency, utilizing proprietary AI-powered imaging to non-invasively analyze biological and material samples. By transforming traditional MRI technology into a fast, scalable, and accessible tool, the company provides critical insights for sectors ranging from sustainable food systems to early-stage disease detection. As a spin-off from the Technical University of Munich, Orbem has established a robust market position by revealing hidden internal data, thereby enabling industries to optimize processes and enhance sustainability through high-fidelity, AI-enhanced diagnostics.
How much funding has Orbem raised?
Orbem has raised a total of $96.6M across 2 funding rounds:
Series A
$31.6M
Series B
$65M
Series A (2023): $31.6M with participation from The Venture Collective, La Famiglia, 83North, and Possible Ventures
Series B (2026): $65M led by Supernova Invest, 83North, Innovation Industries, General Catalyst, Possible Ventures, and The Venture Collective
Key Investors in Orbem
General Catalyst
General Catalyst is a prominent venture capital firm that partners with founders to build enduring enterprises by providing strategic capital and deep operational expertise across multiple growth stages.
83North
83North is a global venture capital firm managing over $2.2 billion, focused on supporting exceptional entrepreneurs to build category-leading companies through collaborative growth strategies.
Supernova Invest
Supernova Invest is a specialized deeptech investor that provides patient capital and industrial expertise to high-growth startups in sectors like healthcare and cleantech.
What's next for Orbem?
With the infusion of this latest capital, Orbem is well-positioned to scale its operations and expand the reach of its imaging solutions into new global markets. The company's strategic roadmap focuses on deepening its technological moat by refining its AI algorithms and increasing the throughput of its imaging systems. As it transitions into a more mature growth phase, Orbem will likely prioritize commercial partnerships and the integration of its technology into large-scale industrial workflows, further cementing its role as a leader in the transformation of biological data utilization.
See full Orbem company page
